1-1 of 1
Authors: on behalf of the EVERLAR study investigators
Journal Article
Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study
The Oncologist, Volume 24, Issue 1, January 2019, Pages 38–46, https://doi.org/10.1634/theoncologist.2017-0622
Published: 23 May 2018
